Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

GlobeNewswire November 9, 2021

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

GlobeNewswire November 4, 2021

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

GlobeNewswire November 2, 2021

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors

GlobeNewswire August 12, 2021

Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates

GlobeNewswire August 4, 2021

Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021

GlobeNewswire July 24, 2021

Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

GlobeNewswire July 7, 2021

Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference

GlobeNewswire June 22, 2021

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire June 21, 2021

Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire June 18, 2021

Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease

GlobeNewswire June 16, 2021

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 24, 2021

Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates

GlobeNewswire May 11, 2021

Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire May 6, 2021

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention

GlobeNewswire May 4, 2021

Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis

GlobeNewswire May 3, 2021

Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference

GlobeNewswire April 27, 2021

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates

GlobeNewswire March 31, 2021

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease

GlobeNewswire March 29, 2021

Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel

GlobeNewswire January 19, 2021